RSS

Roche

Genentech has unveiled positive results from its Phase II LADDER study, which evaluated the efficacy and safety of its investigational Port Delivery System with ranibizumab (PDS) in people with wet age-related macular degeneration (AMD). more

News

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation for Roche’s Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) as a first-line treatment for people with advanced or metastatic HCC more

News

Roche has revealed the results of its Phase III CAPSTONE-2 study in which its investigational oral, single-dose antiviral, baloxavir marboxil, has shown superior efficacy in the primary endpoint of time to improvement of flu symptoms versus placebo. more

News

A multi-target strategic collaboration has been formed between drug discovery and development company, Lodo Therapeutics, and Genentech — a member of the Roche Group. more

News

A strategic partnership has been formed between scientists from Emulate and Roche (F Hoffman La-Roche) for the application of organ-chips in the testing of the efficacy and safety of new antibody therapeutics and combination therapies. more

News

Roche has revealed it will acquire healthcare technology and services company, Flatiron Health, in an agreement that will see the companies leverage their respective expertise to advance industry-wide development and delivery of oncology medicines. more

News

The EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Hemlibra (emicizumab) — Roche’s prophylactic treatment for people with haemophilia A with inhibitors. more

News

With festivities and holidays galore during the latter part of December we thought it would be a good idea to briefly run through some of the pharma news that came out in the run up to Christmas. more

News

Researchers from the UCL Huntington’s Disease Centre have developed a drug that has been shown to be safe and well-tolerated in its first human trial, successfully lowering the level of harmful huntingtin protein in the nervous system more

News

Apps are ever more popular and becoming part of daily routine and lifestyle in this digital age, but how are pharma companies measuring up in this space? more

Opinion

Biotech company, Roche, has announced that the US FDA has accepted its biologics licence application (BLA) and granted priority review for its once-weekly subcutaneous treatment for haemophilia A with factor VIII inhibitors more

News

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. more

News

Biotechnology company, MIMETAS, in collaboration with pharmaceutical company, Roche, has developed an organ-on-a-chip system that supports the evaluation of intestinal permeability in perfused 3D gut tubules when exposed to pharmacological compounds. more

News

Global pharmaceutical company Roche has acquired a mobile diabetes platform to bolster its digital health services. more

News

NHS England has struck a deal with Roche and endorsed by the National Institute for Health and Care Excellence (NICE) to make the breast cancer drug Kadcyla available for routine use on the NHS. more

News

According to the atrial fibrillation (AF) patient survey, performed by the AF Association, the majority of patients currently on a vitamin K antagonist, such as warfarin, would consider self-monitoring to give them freedom from clinic visits. more

News

According to business intelligence provider GBI Research, pharmaceuticals company Roche will be the biggest mover in the neurodegenerative drugs space over the next five years. more

News

Roche, pharmaceutical manufacturer, has optimised its critical solvent-handling operations using Almatec pumps. By Harald Vogl, Almatec more

News

FDA has approved Avastin in combination with paclitaxel and cisplatin or paclitaxel and topotecan for the treatment of metastatic carcinoma of the cervix. more

Jamie Mallinson, GlobalData’s analyst covering oncology and hematology, describes the NICE rejection as "no big surprise". more